Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Delozier

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Breast Cancer Research and Treatment|January 1, 1993
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifenE Garcia-Giralt, Y Ayme, M Carton, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854J A van der Hage, C J van de Velde, J P Julien, et al.
British Journal of Cancer|May 29, 2003
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancerA Lortholary, T Delozier, A Monnier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group StudyP C Clahsen, C J van de Velde, J P Julien, et al.
British Journal of Cancer|September 24, 2004
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancerJ Bonneterre, V Dieras, M Tubiana-Hulin, et al.
La Clinica Terapeutica|August 1, 1994
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]E Garcia-Giralt, C Omodei Zorini, L Ferri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancerR Pérez Carrión, V Alberola Candel, F Calabresi, et al.
Breast Cancer Research and Treatment|November 21, 2008
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyC Falandry, M Debled, T Bachelot, et al.
Breast Cancer Research and Treatment|September 1, 1991
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.)J Lacour, A Laplanche, T Delozier, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 25, 2006
Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma cameraA Andrieux, O Switsers, M H Chajari, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Breast Cancer Research and Treatment|January 1, 1993
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifenE Garcia-Giralt, Y Ayme, M Carton, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854J A van der Hage, C J van de Velde, J P Julien, et al.
British Journal of Cancer|May 29, 2003
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancerA Lortholary, T Delozier, A Monnier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group StudyP C Clahsen, C J van de Velde, J P Julien, et al.
British Journal of Cancer|September 24, 2004
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancerJ Bonneterre, V Dieras, M Tubiana-Hulin, et al.
La Clinica Terapeutica|August 1, 1994
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]E Garcia-Giralt, C Omodei Zorini, L Ferri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancerR Pérez Carrión, V Alberola Candel, F Calabresi, et al.
Breast Cancer Research and Treatment|November 21, 2008
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO studyC Falandry, M Debled, T Bachelot, et al.
Breast Cancer Research and Treatment|September 1, 1991
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.)J Lacour, A Laplanche, T Delozier, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 25, 2006
Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma cameraA Andrieux, O Switsers, M H Chajari, et al.
Pageof 5